Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. freshman Avg
|
|
New words:
abiraterone, absent, ABX, Adaptimmune, Affimed, allogeneic, androgen, antitumor, ANZUP, ASCO, Atara, atom, Atridia, Australian, baseline, beam, bear, Bellicum, beta, Bio, biochemical, Biomedizinische, BioNTech, Bluebird, bypassing, cabazitaxel, calendar, CAM, Celgene, Celyad, Chairman, chemically, choice, CMC, compassionate, conventional, cooperation, cooperative, deduction, differentiating, discretionary, distinct, distinctive, donor, dotted, drafting, energetic, enzalutamide, Erik, error, Evonik, exhaustion, Exit, fact, family, feedback, Forschungsreagenzien, GBq, German, Gilead, gradually, Heidelberg, hematoxicity, highest, highlighted, Hofman, immaterial, Immunocore, intangible, Intellia, intravenously, Intrexon, Isotopen, ITM, Kintor, legacy, lesser, lethal, lutetium, MacCallum, mandate, Marquette, MedImmune, Melbourne, modality, morale, multicenter, NAAD, neurotoxicity, Northwestern, optimum, osteosarcoma, overexpressed, paint, painted, palliative, particle, PCAOB, pilot, point, power, powerful, precursor, prove, provisional, Pty, radiographic, radioligand, RadioMedix, radiotherapy, refocused, regimen, remedial, renal, reorganization, rescue, residual, resold, retention, RLT, roughly, rounded, rulemaking, Scientist, SCRI, shelf, Shortly, Singapore, skeletal, skip, sublicensee, Suzhou, Sydney, symptomatic, syndrome, Takara, talent, Task, taxane, Technologien, TheraP, tiered, titration, travel, Trump, unclear, uncontrolled, unexpected, Unum, VISION, workforce, Zenith
Removed:
abandon, accessibility, accessible, acid, activated, ADC, addressed, adenocarcinoma, advancing, Africa, aggressively, aging, allocation, Amgen, aminopterin, Ann, antibody, Aplin, appeal, appointed, Argentina, ariad, arm, arthritic, attach, Avastin, avoiding, awarded, aware, back, background, Bank, Belgium, beneficially, bevacizumab, billion, biodistribution, biological, biologically, blood, bloodstream, BMS, Boehringer, bowel, brain, Brauer, Brinkley, broaden, burden, Canada, Canadian, carboplatin, Carolina, cellular, Chapel, characteristic, chemotherapeutic, China, circulating, cisplatin, Citigroup, classify, clearance, cleaved, closed, colon, colorectal, commitment, comparable, compartment, competitor, complaint, concentration, confirming, conjugated, connected, consistently, contrast, converted, costimulatory, counsel, County, curative, customized, DAVLBH, deeply, defendant, deficiency, delaying, dense, deprive, derivative, Derivatively, destabilizer, destruction, deterring, District, division, Dohme, dosed, dosing, doubt, doxorubicin, efficiently, Electric, emerged, employ, employing, encompassing, endometrial, endosomal, enriched, enrolling, epothilone, Eric, erlotinib, ESMO, essential, etanercept, extract, extracted, Fannie, featuring, fission, footnote, founded, FR, France, Fred, Freddie, guide, Hage, Hanham, Herceptin, Hill, Home, Hong, hybrid, hydrazide, ideal, iii, image, impractical, incidence, India, indiscriminate, Individually, inflammation, inflammatory, Ingelheim, inhibitor, inhibitory, injectable, intensity, internalization, intestine, inventoried, Israel, Italy, Jamele, JHP, John, judgment, Kappa, Keith, kidney, Kingdom, Kong, Kozin, largest, leading, Lesley, leveraging, linked, linker, linking, liposomal, liver, loan, lung, Mac, Mae, Marc, marked, maturing, MBA, meaningfully, medium, Meldrum, methotrexate, mice, microbiology, microtubule, Middleton, Mike, mitigate, modest, modular, modulate, module, molecular, monoclonal, monotherapy, Moore, MTD, mTOR, multinational, neovasculature, Nguyen, nivolumab, noise, nominal, nonpublic, North, November, NSCLC, nuclide, originating, paclitaxel, parallel, parent, payload, pediatric, pegylated, penetrate, pentanedioic, people, personalize, PFS, pharmacy, PKD, plaintiff, platinum, play, PLD, polycystic, polymerization, poor, posed, potency, preclinical, predefined, premium, prevalence, prevalent, preventing, progressed, projected, proteasome, Puma, purpose, quick, radioisotope, reader, realizing, recurrent, released, releasing, reliable, repeatedly, replaced, replacing, resolution, Revocable, rheumatoid, Rituxan, role, Rubin, Russell, salvage, scan, scanned, scheduled, selective, selectively, selectivity, shareholder, Sharp, shorter, signal, Similarly, simple, Situated, South, Southern, spacer, Spain, Squibb, stability, stable, step, structure, subgroup, subset, Suisse, superior, synthesize, Taiwan, Tc, technetium, termed, Tippecanoe, title, tolerated, topotecan, toxic, toxicology, transport, Trust, TubBH, tubulin, unconjugated, undelivered, understand, Underwriter, underwriting, untargeted, uptake, uranium, USA, usage, validate, validating, Vallabhaneni, Veloso, Venezuela, Verastem, viable, vitamin, vitro, vulnerability, weight, widespread, withdrew, worsening, xenograft
Filing tables
Filing exhibits
Related press release
ECYT similar filings
Filing view
External links
Exhibit 10.26
ENDOCYTE, INC.
SCHEDULE OF TERMS FOR
CHANGE IN CONTROL AND SEVERANCE AGREEMENTS
WITH EXECUTIVE OFFICERS
February 2018
|
| Termination without Cause or Resignation for Good Reason, prior to a Change in Control or after 12 months following a Change in Control | Termination without Cause or Resignation for Good Reason, within 12 months following a Change in Control | |||||
Name of Executive Officer | Date of Agreement | Severance Payment – Percentage of Base Salary | 140% COBRA Continuation | Accelerated vesting for equity awards that would have vested over the following | Severance Payment – Percentage of Base Salary | Severance Payment – Percentage of Target Bonus | 140% COBRA Continuation | Percentage of unvested equity awards that will immediately vest |
Michael A. Sherman | 6/17/16 | 100% | 12 months | 12 months | 200% | 200% | 24 months | 100% |
Michael A. Andriole | 2/20/17 | 75% | 9 months | 9 months | 150% | 150% | 18 months | 100% |
Alison A. Armour | 8/10/15 | 75% | 9 months | 9 months | 150% | 150% | 18 months | 100% |
Beth A. Taylor | 5/15/15 | 75% | 9 months | 9 months | 100% | 100% | 12 months | 100% |
Erik Chelius | 2/21/18 | 75% | 9 months | 9 months | 100% | 100% | 12 months | 100% |
Christopher P. Leamon | 5/15/15 | 75% | 9 months | 9 months | 150% | 150% | 18 months | 100% |
Katherine K. Parker | 5/15/15 | 75% | 9 months | 9 months | 100% | 100% | 12 months | 100% |